Sexual Health Partnering Terms and Agreements

95 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
95
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Sexual Health Partnering Terms and Agreements

  1. 1. Sexual Health Partnering Terms and AgreementsReport Details:Published:September 2012No. of Pages: 595Price: Single User License – US$1995This report provides comprehensive understanding and unprecedented access to the sexualhealth partnering deals and agreements entered into by the worlds leading healthcare companies.The report provides a detailed understanding and analysis of how and why companies entersexual health partnering deals. The majority of deals are discovery or development stage wherebythe licensee obtains a right or an option right to license the licensors sexual health technology.These deals tend to be multicomponent, starting with collaborative R&D, and commercialization ofoutcomes.Understanding the flexibility of a prospective partner’s negotiated deals terms provides criticalinsight into the negotiation process in terms of what you can expect to achieve during thenegotiation of terms. Whilst many smaller companies will be seeking details of the paymentsclauses, the devil is in the detail in terms of how payments are triggered – contract documentsprovide this insight where press releases do not.This report contains over 500 links to online copies of actual sexual health deals and contractdocuments as submitted to the Securities Exchange Commission by companies and theirpartners. Contract documents provide the answers to numerous questions about a prospectivepartner’s flexibility on a wide range of important issues, many of which will have a significantimpact on each party’s ability to derive value from the deal.The initial chapters of this report provide an orientation of sexual health dealmaking and businessactivities. Chapter 1 provides an introduction to the report.Chapter 2 provides an overview of the trends in sexual health dealmaking since 2007 coveringtrends by year, deal type, stage of development, technology type and therapeutic indication. Inaddition the chapter includes an analysis of financial deal terms by stage at signing coveringheadline value, upfront payment, milestone payments and royalty rates. Analysis includes medianvalues and distribution of values for each stage of development.Chapter 3 provides a review of the leading sexual health deals since 2007. Deals are listed byheadline value, signed by bigpharma, most active bigpharma, and most active of all biopharmacompanies. Where the deal has an agreement contract published at the SEC a link providesonline access to the contract.Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a briefsummary followed by a comprehensive listing of sexual health deals, as well as contractdocuments available in the public domain. Where available, each deal title links via Weblink to an
  2. 2. online version of the actual contract document, providing easy access to each contract documenton demand.Chapter 5 provides comprehensive access to all sexual health deals since 2007 where a dealcontract is available, providing the user with direct access to contracts as filed with the SECregulatory authorities. Each deal title links via Weblink to an online version of the deal recordcontract document, providing easy access to each contract document on demand.Chapter 6 provides a comprehensive directory of all sexual health partnering deals signed andannounced since 2007. The chapter is organized by specific sexual health therapy focus. Eachdeal title links via Weblink to an online version of the deal record and where available, the contractdocument, providing easy access to each contract document on demand.In addition, a comprehensive appendix is provided with each report of all sexual health partneringdeals signed and announced since 2007. The appendices are organized by company A-Z, stageof development at signing, deal type (collaborative R&D, co-promotion, licensing etc) andtechnology type. Each deal title links via Weblink to an online version of the deal record and whereavailable, the contract document, providing easy access to each contract document on demand.The report also includes numerous tables and figures that illustrate the trends and activities insexual health partnering and dealmaking since 2007.In conclusion, this report provides everything a prospective dealmaker needs to know aboutpartnering in the research, development and commercialization of sexual health technologies andproducts.Sexual Health Partnering Terms and Agreements provides the reader with the following keybenefits:•In-depth understanding of sexual health deal trends since 2007•Access sexual health deal headline, upfront, milestone and royalty data•Research hundreds of actual contracts between sexual health partner companies•Comprehensive access to over 500 links to actual sexual health deals entered into by the world’s biopharma companies•Indepth review of sexual health deals entered into by the leading fifty bigpharma companies•Benchmark the key deal terms companies have agreed in previous deals•Identify key terms under which companies partner sexual health opportunities•Uncover companies actively partnering sexual health opportunitiesGet your copy of this report @http://www.reportsnreports.com/reports/191589-sexual-health-partnering-terms-and-agreements.htmlMajor points covered in Table of Contents of this report includeTable of ContentsExecutive SummaryChapter 1 – IntroductionChapter 2 – Trends in sexual health dealmaking2.1. Introduction2.2. Sexual health partnering over the years
  3. 3. 2.3. Bigpharma sexual health dealmaking activity2.4. Bigpharma not active in sexual health2.5. Sexual health partnering by deal type2.6. Sexual health partnering by industry sector2.7. Sexual health partnering by stage of development2.8. Sexual health partnering by technology type2.9. Sexual health partnering by sexual health indication2.10. Average deal terms for Sexual health2.10.1 Sexual health headline values2.10.2 Hematology upfront payments2.10.3 Sexual health milestone payments2.10.4 Sexual health royalty ratesChapter 3 – Leading sexual health deals3.1. Introduction3.2. Top sexual health deals by value3.3. Top sexual health deals involving bigpharmaChapter 4 – Bigpharma sexual health deals4.1. Introduction4.2. How to use bigpharma partnering deals4.3. Bigpharma sexual health partnering company profilesAbbottBayerGlaxoSmithKlineMenariniMerck & CoMylanPfizerRocheTevaValeantWarner ChilcottWatsonChapter 5 – Sexual health partnering contracts directory5.1. Introduction5.2. By deal typeAsset purchaseCollaborative R&DDevelopmentDistributionJoint ventureLicensingManufacturing
  4. 4. MarketingMaterial transferSettlementSub-licenseTermination5.3. By stage of developmentFormulationMarketedPhase IIPhase IIIPreclinicalRegulatory5.4. By technology typeBiological compoundsDevicesDiagnosticsDrug deliverySmall moleculesChapter 6 – Sexual health dealmaking by indication6.1. Introduction6.2. Deals by therapeutic indicationSexual HealthBacterial vaginosisCandida albicans (Thrush)ContraceptionErectile dysfunctionSexual dysfunctionSexually transmitted disease (STI)ChlamydiaGenital wartsGonorrheaHerpesSyphilisTrichomoniasisChapter 7 – Partnering resource center7.1. Online partnering7.2. Partnering events7.3. Further reading on dealmakingAppendicesAppendix 1 – Directory of sexual health deals by company A-Z 2007-2012Appendix 2 – Directory of sexual health deals by deal type 2007-2012Appendix 3 – Directory of sexual health deals by stage of development 2007-2012
  5. 5. Appendix 4 – Directory of sexual health deals by technology type 2007-2012Appendix 5 – Deal type definitionsAbout Wildwood VenturesCurrent PartneringCurrent AgreementsRecent titles from CurrentPartneringOrder Form – ReportsOrder Form – Therapy ReportsList of FiguresFigure 1: Sexual health partnering since 2007Figure 2: Bigpharma – top 50 – sexual health deals 2007 to 2012Figure 3: Bigpharma sexual health deal frequency – 2007 to 2012Figure 4: Inactive bigpharma in sexual health 2007-2012Figure 5: Sexual health partnering by deal type since 2007Figure 6: Sexual health partnering by industry sector since 2007Figure 7: Sexual health partnering by stage of development since 2007Figure 8: Sexual health partnering by technology type since 2007Figure 9: Sexual health partnering by sexual health target since 2007Figure 10: Sexual health deals with a headline valueFigure 11: Sexual health deal headline value distribution, US$million – discovery stageFigure 12: Sexual health deal headline value distribution, US$million – preclinical stageFigure 13: Sexual health deal headline value distribution, US$million – phase I stageFigure 14: Sexual health deal headline value distribution, US$million – phase II stageFigure 15: Sexual health deal headline value distribution, US$million – phase III stageFigure 16: Sexual health deal headline value distribution, US$million – regulatory stageFigure 17: Sexual health deal headline value distribution, US$million – marketed stageFigure 18: Summary median headline value by stage of development, 2007-2012Figure 19 Sexual Health deals with upfront payment valuesFigure 20: Sexual health deal upfront payment distribution, US$million – discovery stageFigure 21: Sexual health deal upfront payment distribution, US$million – preclinical stageFigure 22: Sexual health deal upfront payment distribution, US$million – phase I stageFigure 23: Sexual health deal upfront payment distribution, US$million – phase II stageFigure 24: Sexual health deal upfront payment distribution, US$million – phase III stageFigure 25: Sexual health deal upfront payment distribution, US$million – regulatory stageFigure 26: Sexual health deal upfront payment distribution, US$million – marketed stageFigure 27: Summary median upfront payments by stage of development, 2007-2012Figure 28: Sexual health deals with milestone paymentsFigure 29: Sexual health deal milestone distribution, US$million – discovery stageFigure 30: Sexual health deal milestone distribution, US$million – preclinical stageFigure 31: Sexual health deal milestone distribution, US$million – phase I stageFigure 32: Sexual health deal milestone distribution, US$million – phase II stageFigure 33: Sexual health deal milestone distribution, US$million – phase III stage
  6. 6. Figure 34: Sexual health deal milestone distribution, US$million – regulatory stageFigure 35: Sexual health deal milestone distribution, US$million – marketed stageFigure 36: Sexual health deals with royalty rates, %Figure 37: Sexual health deal royalty rate distribution, US$million – discovery stageFigure 38: Sexual health deal royalty rate distribution, US$million – preclinical stageFigure 39: Sexual health deal royalty rate distribution, US$million – phase I stageFigure 40: Sexual health deal royalty rate distribution, US$million – phase II stageFigure 41: Sexual health deal royalty rate distribution, US$million – phase III stageFigure 42: Sexual health deal royalty rate distribution, US$million – regulatory stageFigure 44: Summary median royalty rate by stage of development, 2007-2012Figure 45: Top sexual health deals by value since 2007Figure 46: Top sexual health deals signed by bigpharma value since 2007Figure 47: Online partnering resourcesFigure 48: Forthcoming partnering eventsContact: sales@reportsandreports.com for more information.

×